Here, we discuss FSHD biomarkers and pathomechanisms, focussing on bottom‐up approaches centred on DUX4 and top‐down approaches aligned to PAX7, and consider how the relationship between these two transcription factors may explain some unanswered questions. The gene discussed is PAX7; the disease is facioscapulohumeral muscular dystrophy.